ROCO
4194
Market cap33mUSD
Jun 16, Last price
7.05TWD
1D
0.14%
1Q
-29.43%
Jan 2017
-61.68%
IPO
-92.14%
Name
Holy Stone Healthcare Co Ltd
Chart & Performance
P/E
—
P/S
8.24
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.31%
Rev. gr., 5y
-10.27%
Revenues
119m
-49.86%
Net income
-183m
L-36.59%
CFO
-143m
L-48.55%
Profile
Holy Stone Healthcare Co., Ltd. engages in the research, development and manufacture of hyaluronic acid drugs and medical devices. It offers injectable devices for osteoarthritis and soft tissue injuries. The company also provides hyaluronic acid and mesalamine capsules for inflammatory bowel diseases. Holy Stone Healthcare was founded on January 18, 2001 and is headquartered in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 118,766 -49.86% | 236,890 -12.34% | 270,243 24.49% | |||
Cost of revenue | 308,575 | 525,180 | 420,212 | |||
Unusual Expense (Income) | ||||||
NOPBT | (189,809) | (288,290) | (149,969) | |||
NOPBT Margin | ||||||
Operating Taxes | 26 | 4,947 | 6,507 | |||
Tax Rate | ||||||
NOPAT | (189,835) | (293,237) | (156,476) | |||
Net income | (183,493) -36.59% | (289,370) 89.20% | (152,943) -15.64% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 391,000 | 400,000 | ||||
BB yield | -21.96% | -10.88% | ||||
| Debt | ||||||
Debt current | 4,722 | 64,301 | 11,407 | |||
Long-term debt | 23,998 | 29,719 | 40,898 | |||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (237,960) | 7,640 | (392,926) | |||
| Cash flow | ||||||
Cash from operating activities | (142,655) | (277,294) | (145,936) | |||
CAPEX | (2,100) | (3,530) | (2,149) | |||
Cash from investing activities | (2,160) | (141,365) | (3,198) | |||
Cash from financing activities | 325,141 | 51,165 | 390,720 | |||
FCF | (173,419) | (271,298) | (164,593) | |||
| Balance | ||||||
Cash | 266,680 | 85,777 | 445,231 | |||
Long term investments | 603 | |||||
Excess cash | 260,742 | 74,536 | 431,719 | |||
Stockholders' equity | 129,049 | 62,970 | 279,829 | |||
Invested Capital | 179,383 | 97,407 | 267,248 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 137,507 | 136,622 | 120,289 | |||
Price | 12.95 -31.88% | 19.01 -37.81% | 30.57 5.85% | |||
Market cap | 1,780,716 -31.44% | 2,597,184 -29.37% | 3,677,243 15.79% | |||
EV | 1,542,756 | 2,604,824 | 3,284,317 | |||
EBITDA | (177,734) | (270,982) | (132,529) | |||
EV/EBITDA | ||||||
Interest | 637 | 700 | 624 | |||
Interest/NOPBT | ||||||